Sec Form 3 Filing - Chiang Kyle @ LogicBio Therapeutics, Inc. - 2020-11-02

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Chiang Kyle 2. Issuer Name and Ticker or Trading Symbol LogicBio Therapeutics, Inc. [ LOGC] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Operating Officer (Last) (First) (Middle) C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVE, FLOOR 2 3. Date of Earliest Transaction (MM/DD/YY) 11/02/2020 (Street) LEXINGTON, MA02421 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 17,004 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Option to purchase Common Stock $ 0.5 ( 1 ) 10/18/2026 Common Stock 8,001 D Option to purchase Common Stock $ 0.73 ( 2 ) 11/02/2027 Common Stock 24,052 D Option to purchase Common Stock $ 0.73 ( 3 ) 01/31/2028 Common Stock 22,906 D Option to purchase Common Stock $ 10.1 ( 4 ) 10/23/2028 Common Stock 23,000 D Option to purchase Common Stock $ 7.11 ( 5 ) 02/11/2030 Common Stock 28,921 D Restricted Stock Units ( 6 ) $ 0 ( 7 ) ( 7 ) Common Stock 9,360 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Chiang Kyle C/O LOGICBIO THERAPEUTICS, INC. 65 HAYDEN AVE, FLOOR 2 LEXINGTON, MA02421 Chief Operating Officer Signatures /s/ Jonathan Quick, as Attorney-in-Fact 11/12/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The option vested 25% on the first anniversary of the vesting commencement date, October 17, 2017, and in equal one forty-eighth monthly installments thereafter. ( 2 )The option vested 10% on November 19, 2017, and in equal one forty-eighth monthly installments thereafter. ( 3 )The option began vesting in equal one forty-eighth monthly installments beginning on February 1, 2018. ( 4 )The option began vesting in equal one forty-eighth monthly installments beginning on November 30, 2018. ( 5 )25% vests on 01/01/2021 and the remainder vests in equal monthly installments over the next 36 months. ( 6 )Each restricted stock unit ("RSU") represents a contingent right to receive one share of LogicBio Therapeutics Inc. (the "Company") common stock. ( 7 )The RSUs will fully vest on April 15, 2021, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan; provided, that if the reporting person's employment is terminated by the Company without "cause" or by the reporting person for "good reason" (as defined in the reporting person's employment agreement) prior to April 15, 2021, all such RSUs will vest on the date of termination.

Remarks: Exhibit List: 24.1 Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.